- Signal Genetics (SGNL) enters into an agreement with Tampa, FL-based Moffitt Cancer Center to further validate the clinical utility of the company's MyPRS test in multiple myeloma (MM) and its precursor conditions, smoldering multiple myeloma and asymptomatic monoclonal gammopathies (AMG). Under the terms of the agreement, Signal will perform MyPRS testing on patient specimens to assist in patient management decisions, including the risk of progression from AMG to symptomatic MM.
-
MyPRS (Myeloma Prognostic Risk Signature) is a gene expression profiling assay that helps distinguish patients along the spectrum of the condition.
- Shares are up 20% premarket on light volume.